dbACP: A Comprehensive Database of Anti-Cancer Peptides

dbacp01854

General Description

Peptide name : Bombina orientalis Bombinin H-BO3

Source/Organism : Oriental Fire-bellied Toad Bombinin H-BO1

Linear/Cyclic : Not found

Chirality : Not found

Sequence Information

Sequence : GIGSAILSAGKSIIKGLAKGLAEHF

Peptide length: 25

C-terminal modification: Not found

N-terminal modification : Amidation

Non-natural peptide information: None

Activity Information

Assay type : MTT assay

Assay time : 48h

Activity : IC50 : 3.61 μM

Cell line : Hep G2

Cancer type : Human hepatoma

Other activity : Not found

Physicochemical Properties

Amino acid composition bar chart :

Molecular mass : 2438.8625 Dalton

Aliphatic index : 1.252

Instability index : -6.84

Hydrophobicity (GRAVY) : 0.664

Isoelectric point : 9.7032

Charge (pH 7) : 1.8471

Aromaticity : 0.04

Molar extinction coefficient (cysteine, cystine): (0, 0)

Hydrophobic/hydrophilic ratio : 2.125

hydrophobic moment : -1.101

Missing amino acid : C,R,W,Q,T,P,M,D,Y,N,V

Most occurring amino acid : G

Most occurring amino acid frequency : 5

Least occurring amino acid : E

Least occurring amino acid frequency : 1

Structural Information

3D structure :

Secondary structure fraction (Helix, Turn, Sheet): (0.4, 0.3, 0.3)

SMILES Notation: CC[C@H](C)[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC

Secondary Structure :

Method Prediction
GOR ECCEEEHHHTHHHEHHHHHHHHHHH
Chou-Fasman (CF) EEEEEECCCEEEEEHHHHHHHHCCC
Neural Network (NN) CCCCEEECCCCCHHHHHHHHHHHHH
Joint/Consensus CCCEEECCCCCCCCHHHHHHHHHHH

Molecular Descriptors and ADMET Properties

Molecular Descriptors: Click here to download

ADMET Properties: Click here to download

Cross Referencing databases

Pubmed Id : 29098406

Uniprot : Not available

PDB : Not available

CancerPPD : Not available

ApIAPDB : Click Here

CancerPPD2 ID : Not available

Reference

1 : Peng X, et al. Molecular characterization and bioactivity evaluation of two novel bombinin peptides from the skin secretion of Oriental fire-bellied toad, Bombina orientalis. Amino Acids. 2018; 50:241-253. doi: 10.1007/s00726-017-2509-z

Literature

Paper title : Molecular characterization and bioactivity evaluation of two novel bombinin peptides from the skin secretion of Oriental fire-bellied toad, Bombina orientalis.

Doi : https://doi.org/10.1007/s00726-017-2509-z

Abstract : Following the exploration of biochemicals in amphibian defensive skin secretion, great attention has been focused on the novel bioactive peptides with unique molecular structures and complicated features and functions. In this study, the skin secretion of Oriental fire-bellied toad, Bombina orientalis, was acquired to search peptides with therapeutic potential. Using "shotgun" cloning technique, a full-length peptide precursor co-encoding two novel bombinin peptides was cloned from the skin secretion-derived cDNA library of B. orientalis. The deduced peptides were identified as one bombinin-like peptide (BLP) (GIGSAILSAGKSIIKGLAKGLAEHF-NH<sub>2</sub>) and one bombinin H-type peptide (BH) (IIGPVLGLVGKALGGLL-NH<sub>2</sub>). The primary structures of both peptides were confirmed through reverse-phase HPLC fractionation and mass spectrometry. Secondary structural prediction revealed Bombinin-BO1 and Bombinin H-BO1 adopted α-helical structural features. In addition, the two peptides exhibited broad-spectrum antimicrobial effect against Gram-positive and Gram-negative bacteria and yeast. Meanwhile, the anticancer activity assay indicated both peptides exerted significant anticancer effects against human hepatoma cell lines tested (Hep G2/SK-HEP-1/Huh7). The peptides reported here for the first time may represent novel lead compounds for the design/development of new therapeutics for human infection and neoplastic disease.